Kanada - angličtina - Health Canada

schering-plough canada inc - beclomethasone dipropionate - metered-dose aerosol - 50mcg - beclomethasone dipropionate 50mcg - anti-inflammatory agents

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

brupharmexport sprl - paracetamol - tablets - 500mg

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

clinuvel pharmaceuticals ltd - afamelanotide acetate, quantity: 18 mg - implant - excipient ingredients: polyglactin - scenesse is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (epp)

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 1000 mg - canasa® 1000 mg suppositories are indicated for the treatment of active ulcerative proctitis. canasa® 1000 mg suppositories are contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated vegetable fatty acid esters (hard fat, nf)], or to salicylates (including aspirin).

Spojené státy - angličtina - NLM (National Library of Medicine)

mckesson rxpak inc - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 1000 mg - canasa is indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. canasa is contraindicated in patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any ingredients in the suppository vehicle [see warnings and precautions (5.3), adverse reactions (6.2), and description (11)] . risk summary limited published data on mesalamine use in pregnant women are insufficient to inform a drug-associated risk. no evidence of teratogenicity was observed in rats or rabbits when treated during gestation with orally administered mesalamine at doses greater than the recommended human intra-rectal dose [see data] . the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnanci

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, conjugated synthetic a (unii: jm2621p2ls) (estrogens, conjugated synthetic a - unii:jm2621p2ls) - estrogens, conjugated synthetic a 0.45 mg - cenestin therapy is indicated for the: 1. treatment of moderate-to-severe vasomotor symptoms associated with the menopause. - 0.45 mg cenestin - 0.625 mg cenestin - 0.9 mg cenestin - 1.25 mg cenestin 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - 0.3 mg cenestin cenestin should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - cenestin therapy should not be used in patients with known hypersensitivity to its ingredients. - known or su

Spojené státy - angličtina - NLM (National Library of Medicine)

allergan, inc. - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 1000 mg - canasa is indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. canasa is contraindicated in patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any ingredients in the suppository vehicle [ s ee warnings and precautions ( 5.3 ), adverse reactions ( 6.2 ), and description ( 11 )] . risk summary limited published data on mesalamine use in pregnant women are insufficient to inform a drug-associated risk. no evidence of teratogenicity was observed in rats or rabbits when treated during gestation with orally administered mesalamine at doses greater than the recommended human intra-rectal dose ( see data ) . the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recogni

Spojené státy - angličtina - NLM (National Library of Medicine)

clinuvel inc. - afamelanotide (unii: qw68w3j66u) (afamelanotide - unii:qw68w3j66u) - scenesse® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp). none.

Spojené státy - angličtina - NLM (National Library of Medicine)

csm clinical supplies management europe gmbh - afamelanotide (unii: qw68w3j66u) (afamelanotide - unii:qw68w3j66u) - scenesse® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp). none. the safety and effectiveness of scenesse have not been established in pediatric patients. there were 10 subjects 65 years old and over in the clinical studies for epp [see clinical studies (14)]. of the 125 subjects treated with scenesse in these studies, 4 (3%) were 65 years of age and older. clinical studies of scenesse did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Japonsko - angličtina - すりの適正使用協議会 RAD-AR Council, Japan

meiji seika pharma co., ltd. - sanactase m; proctase; olipase 2s; meicelase; pancreatic digestive enzyme ta - white tablet, φ: 10.7 mm, thickness: 5.7 mm